Annexin A2, also known as ANXA2, is a protein that controls cellular development and is reliant on calcium to bind to phospholipids. ANXA2 has a role in a variety of pathophysiological processes, including the shift from epithelial to mesenchymal cells, fibrinolysis, and cancer treatment resistance. By stimulating the MYC-HIF1A-VEGF signaling cascade, ANXA2 made it easier for esophageal squamous carcinoma cells to migrate and invade surrounding tissue. Our study showed the DIC score with D-Dimer and ANXA2 had a highly significant (p-value 0.0001) positive correlation with each acute leukemia patient group (ALL and AML), and  H3 had a significant (p-value <0.05) positive correlation with AML more than ALL groups, while PDGF-BB revealed significant highly significant (p-value 0.0001) positive correlation with ALL more than AML patients. To predict the severity of DIC in acute leukemia patients we studied the association between study parameters with acute leukemia patients and we found the NNXA2 and D-Dimer, group age under 18 highly significant (p-value <0.05) increased severity of DIC in acute leukemia patients.